The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 6 results:
[ Author(Desc)] Title Type Year
Filters: Author is Katopodi, Theodora  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
K
Katopodi, T., Petanidis S., Anestakis D., Charalampidis C., Chatziprodromidou I., Floros G., et al. (2023).  Immunoengineering via Chimeric Antigen Receptor-T Cell Therapy: Reprogramming Nanodrug Delivery.. Pharmaceutics. 15(10), 
Katopodi, T., Petanidis S., Grigoriadou E., Anestakis D., Charalampidis C., Chatziprodromidou I., et al. (2024).  Immune Specific and Tumor-Dependent mRNA Vaccines for Cancer Immunotherapy: Reprogramming Clinical Translation into Tumor Editing Therapy.. Pharmaceutics. 16(4), 
Katopodi, T., Petanidis S., Anestakis D., Charalampidis C., Chatziprodromidou I., Floros G., et al. (2023).  Tumor cell metabolic reprogramming and hypoxic immunosuppression: driving carcinogenesis to metastatic colonization.. Front Immunol. 14, 1325360.
Katopodi, T., Petanidis S., Tsavlis D., Anestakis D., Charalampidis C., Chatziprodromidou I., et al. (2022).  Engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy.. Front Oncol. 12, 1042125.
Katopodi, T., Petanidis S., Charalampidis C., Chatziprodromidou I., Eskitzis P., Tsavlis D., et al. (2022).  Tumor-Infiltrating Dendritic Cells: Decisive Roles in Cancer Immunosurveillance, Immunoediting, and Tumor T Cell Tolerance.. Cells. 11(20), 
Katopodi, T., Petanidis S., Domvri K., Zarogoulidis P., Anestakis D., Charalampidis C., et al. (2021).  Kras-driven intratumoral heterogeneity triggers infiltration of M2 polarized macrophages via the circHIPK3/PTK2 immunosuppressive circuit.. Sci Rep. 11(1), 15455.

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.